Madrigal Pharmaceuticals, Inc.
MDGL
Rang în acțiuni
#1999
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Preț acțiune
$451.08
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$10.42B
Schimbare (1 zi)
-1.90%
Schimbare (1 an)
2.77%
Țară
US
Tranzacționează Madrigal Pharmaceuticals, Inc. (MDGL)
Categorie
Healthcare
EPS pentru Madrigal Pharmaceuticals, Inc. (MDGL)
EPS la data de June 2026 TTM: $-12.89
Conform celor mai recente rapoarte financiare și prețului acțiunilor Madrigal Pharmaceuticals, Inc., EPS-ul actual al companiei (TTM) este $-12.89. La sfârșitul anului 2023, compania avea un EPS de $-19.99 o creștere față de EPS-ului din 2022, care a fost de $-17.23.
Istoricul EPS pentru Madrigal Pharmaceuticals, Inc. din 2001 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-12.89 | -41.14% |
| 2024 | $-21.90 | 9.55% |
| 2023 | $-19.99 | 16.02% |
| 2022 | $-17.23 | 17.77% |
| 2021 | $-14.63 | 11.76% |
| 2020 | $-13.09 | 176.74% |
| 2019 | $-4.73 | 113.06% |
| 2018 | $-2.22 | -12.60% |
| 2017 | $-2.54 | -49.90% |
| 2016 | $-5.07 | -98.74% |
| 2015 | $-401.56 | 1,211.43% |
| 2014 | $-30.62 | -31.16% |
| 2013 | $-44.48 | 20.25% |
| 2012 | $-36.99 | 5.26% |
| 2011 | $-35.14 | 8.16% |
| 2010 | $-32.49 | -139.84% |
| 2009 | $81.55 | -184.87% |
| 2008 | $-96.09 | 40.38% |
| 2007 | $-68.45 | -23.97% |
| 2006 | $-90.03 | -16.88% |
| 2005 | $-108.31 | 26.00% |
| 2004 | $-85.96 | 92.52% |
| 2003 | $-44.65 | -57.51% |
| 2002 | $-105.09 | 2,209.67% |
| 2001 | $-4.55 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -234.37% |
US
|
|
| $-7.98 | -38.09% |
US
|
|
| $-5.29 | -58.96% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -315.21% |
NL
|
